JNJ 70075200
Alternative Names: JNJ-70075200Latest Information Update: 29 Mar 2021
At a glance
- Originator Janssen Research & Development
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 09 Mar 2021 Preclinical trials in Unspecified in USA (PO) before March 2021 (NCT04782661)
- 09 Mar 2021 Janssen Research & Development plans a phase I trial in Healthy Volunteers (In adults) in Netherlands (PO, Liquid) in March 2021 (NCT04782661) (EudraCT 2020-004946-12)